 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «123 |
- | Cdactin-O (CBM-588) / Osel, Miyarisan
Journal: Clostridium butyricum MIYAIRI 588 Modifies Bacterial Composition under Antibiotic-Induced Dysbiosis for the Activation of Interactions via Lipid Metabolism between the Gut Microbiome and the Host. (Pubmed Central) - Aug 28, 2021
This is the first study to report that CBM 588 influences the interrelationship between colon tissue and the gut microbiome through lipid metabolism. These findings provide insights into the mechanisms of prevention and recovery from inflammation and the improvement of host metabolism by CBM 588.
- | Cdactin-O (CBM-588) / Osel, Miyarisan
Journal: The Butyrate-Producing Bacterium Clostridium butyricum Suppresses Clostridioides difficile Infection via Neutrophil- and Antimicrobial Cytokine-Dependent but GPR43/109a-Independent Mechanisms. (Pubmed Central) - Aug 26, 2021
However, GPR43 and GPR109a, two G protein-coupled receptors activated by butyrate, were dispensable for the protective effect of CBM588. These results indicate that CBM588 and butyrate suppress CDI, in part by boosting antimicrobial innate and cytokine-mediated immunity.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date, Combination therapy, Metastases: P30CA033572: CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (clinicaltrials.gov) - Aug 18, 2021
P1, N=30, Recruiting, Sponsor: City of Hope Medical Center
These results indicate that CBM588 and butyrate suppress CDI, in part by boosting antimicrobial innate and cytokine-mediated immunity. Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2023
- ||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM-588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: 📝in @NatureComms offers additional MOA for #butyrate-producing #bacteria like C. Butyricum enhancing efficacy of #IO, an early observation in study by @LuisMezaco @NazliDizman @PauloBergerot presented at #ASCO21 this year (nivo/ipi +/- #CBM588 in #kidneycancer). (Twitter) - Jul 27, 2021
- || Cdactin-O (CBM-588) / Osel, Miyarisan
Clinical, Journal: Analysis of ileostomy stool samples reveals dysbiosis in patients with high-output stomas. (Pubmed Central) - Jul 22, 2021
After the exclusion of those treated with the probiotic Miya-BM, whose principal component is C. butyricum, analyses revealed no significant differences between the high-output and low-output groups. This pilot study provides the first evidence correlating gut microbiota with the pathogenesis of high- output stoma compared with low-output stoma.
- |||||| Better late than never? Just now reviewing presentations from #ASCO21. Here's a stellar update on #kidneycancer novel tx from @AlbigesL at @ASCO incl #CTX130, #NKTR214, #CBM588, #rucaparib & much more! Excellent overview! (Twitter) - Jul 22, 2021
- ||| Cdactin-O (CBM-588) / Osel, Miyarisan
Clinical: Microbiome analysis showed a statistically significant increase in Bifidobacteria in CBM588 treated clinical responders compared to CBM588 treated non-clinical responders or SOC patients. @BW_Health @BusinessWire @montypal @LuisMezaco #ASCO2021 https://t.co/2KVP2Xga6U (Twitter) - Jun 11, 2021
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM-588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
#ASCO21 ＃4513 ホンマかいなww Nivo+Ipiに整腸剤（CBM-588, 多分日本で言うミヤBM？）を上乗せすると奏効率もPFSも良くなる。たった29例のP1bなので症例数増やしてフォロー期間も延ばさないとなんとも言えないと思うけど。 (Twitter) - Jun 6, 2021
- ||| Cdactin-O (CBM-588) / Osel, Miyarisan
@scserendipity1 @HHammersMD. We did not see an impact on toxicity with CBM588. Grade 3/4 AEs 50% vs. 43% in the control and intervention arms, respectively. (Twitter) - Jun 6, 2021
- ||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM-588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
The 1st @Uromigos podcast of #ASCO21? I am honored! Thx @tompowles1 & @brian_rini for the chat re: @LuisMezaco's @ASCO PD on nivo/ipi +/- CBM588. Building on @ScienceMagazine papers from @JenWargoMD @diwakardavar et al, we feel we have an effective #microbiome modulator here. https://t.co/PJFdGzgU7Y (Twitter) - Jun 6, 2021
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM-588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
Very interesting results of Ph1B trial with Ipi-Nivo + CBM-588 (C. butyricum to modulate gut microbiota) @CityofHope_GU. Although small numbers, much higher ORR with Ipi-Nivo + CMB-588 (58%) compared to Ipi-Nivo alone (20%) #ASCO21 @OncoAlert (Twitter) - Jun 6, 2021
- || Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM-588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
Agree, but will add nivo/ipi +/- CBM588: ORR 58% x 20% and provocative longer PFS and OS @montypal @LuisMezaco #ASCO21 (Twitter) - Jun 5, 2021
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Cdactin-O (CBM-588) / Osel, Miyarisan
Thanks @DrChoueiri - excited to announce that @LuisMezaco & @JasnoorMalhotra have written a follow-up study exploring #CaboNivo +/- #CBM588 using a similar design. Hypothesis generating, but will tease out impact of TKI. #ASCO21 @neerajaiims @PGrivasMDPhD (Twitter) - Jun 5, 2021
- |||| Cdactin-O (CBM-588) / Osel, Miyarisan
Andrea, we should connect over this. Would love to discuss an interventional trial in #bladdercancer using CBM588. Ping me after #ASCO21? @DrChoueiri @neerajaiims @LuisMezaco @NazliDizman @PauloBergerot @TGen @BladderCancerUS (Twitter) - Jun 5, 2021
- ||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM-588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: Congratulations to @LuisMezaco and amazing mentor @montypal for this groundbreaking work showing prebiotic CBM588 shifts microbiome and associated with greater benefit for RCC patients from ipi/nivo. @cityofhope #ASCO21 (Twitter) - Jun 5, 2021
- ||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM-588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: Interesting study by @LuisMezaco @CityofHope_GU Nivo+Ipi alone or with CBM-588 in patients with mRCC, highlighting the potential role of the microbiome in response to ICIs!! #ASCO21 @ASCO @ASCOPost @ASCO_pubs @NazliDizman @PauloBergerot @montypal (Twitter) - Jun 4, 2021
- |||| Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM-588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker: Lot of great ones: CANTATA with Dr Tannir, F/u for KEYNOTE426 @brian_rini, nivo/ipi/CBM588 @montypal, nivo/ipi and brain Mets @HamidEmamekhoo, biomarkers from javelin101 @DrChoueiri, PROSPER update @allaf_mo to name only a few. Lot of admirable work being done all around (Twitter) - May 20, 2021
- || Cdactin-O (CBM-588) / Osel, Miyarisan, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal: Intestinal Care Using L‒Glutamine Supplement and Probiotics Can Induce a Strong Anti‒Tumor Immune Response through the Induction of Mature Tertiary Lymphoid Structures in Pancreatic Cancer Patients Receiving Preoperative Chemotherapy (Pubmed Central) - May 19, 2021
Recently, we found that intestinal care using oral L‒glutamine‒ enriched supplement and probiotics including Lactobacillus casei Shirota supplement(Yakult®)and Clostridium butyricum MIYAIRI 588 strain(Miya‒BM®)could induce a strong anti‒tumor immune response through the induction of fully mature tertiary lymphoid structures in some pancreatic cancer patients who received 3 cycles of preoperative chemotherapy(gemcitabine 1,000 mg/m2 plus nab‒paclitaxel 125 mg/m2 on days 1, 8, and 15 of 28‒day cycle). In this review article, we discussed the role of intestinal care in the induction of fully mature tertiary lymphoid structures in cancer patients receiving chemotherapy.
- Cdactin-O (CBM-588) / Osel, Miyarisan
[VIRTUAL] Clostridium butyricum MIYAIRI 588 modifies lipid metabolism by the changing gut microbiota composition () - May 8, 2021 - Abstract #ECCMID2021ECCMID_517;
This result may be strongly associated with the previously reported induction of anti-inflammatory lipid mediators by administration of CBM588 . Hence, our results suggested that the metabolic function of the gut microbiome was altered with CBM 588 administration to modifies lipid metabolism to upregulate anti-inflammatory lipid mediators
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
[VIRTUAL] First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2023;
P1
This is the first randomized, prospective study to suggest enhancement of ICI response with a live bacterial product . The observed clinical impact is corroborated by biologic findings supporting gut modulation by CBM-588.
- | Cdactin-O (CBM588) / Osel, Miyarisan
Phase classification: CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (clinicaltrials.gov) - Oct 16, 2019
P1, N=36, Recruiting, Sponsor: City of Hope Medical Center
The observed clinical impact is corroborated by biologic findings supporting gut modulation by CBM-588. Phase classification: P1/2 --> P1
- | Cdactin-O (CBM588) / Osel, Miyarisan
Phase classification: CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (clinicaltrials.gov) - Aug 20, 2019
P1/2, N=30, Recruiting, Sponsor: City of Hope Medical Center
Phase classification: P1/2 --> P1 Phase classification: P1 --> P1/2
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Combination therapy, Metastases: P30CA033572: CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (clinicaltrials.gov) - Apr 29, 2019
P1, N=30, Recruiting, Sponsor: City of Hope Medical Center
Phase classification: P1 --> P1/2 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cdactin-O (CBM588) / Osel, Miyarisan, Yervoy (ipilimumab) / Ono Pharma, BMS
New P1 trial, Combination therapy, Metastases: P30CA033572: CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (clinicaltrials.gov) - Feb 4, 2019
P1, N=30, Not yet recruiting, Sponsor: City of Hope Medical Center
- Cdactin-O (CBM-588) / Osel, Miyarisan
Trial withdrawal: Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections (clinicaltrials.gov) - Nov 7, 2013
P2, N=0, Withdrawn, Sponsor: Osel, Inc.
Not yet recruiting --> Recruiting Terminated --> Withdrawn